+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Comparison of the Efficacy of Dexamethasone, Ondansetron, and Ondansetron Plus Dexamethasone as Antiemetic and Antipruritic Therapy in Patients Receiving Intrathecal Morphine

Comparison of the Efficacy of Dexamethasone, Ondansetron, and Ondansetron Plus Dexamethasone as Antiemetic and Antipruritic Therapy in Patients Receiving Intrathecal Morphine

Anesthesiology Abstracts of Scientific Papers Annual Meeting ( ): Abstract No A-73

Background: Intrathecal opioids are commonly administered to patients for postoperative pain relief. The incidence of postoperative nausea and vomiting (PONV) and pruritus associated with the use of intrathecal opioids is 60-80%(1) and 20-90% (2), respectively. Both ondansetron and dexamethasone reduce the incidence of PONV and pruritus after intrathecal opioid administration. We hypothesised that the combination therapy of dexamethasone and ondansetron would reduce the incidence of intrathecal opioid induced PONV and pruritus more effectively than monotherapy with either agent alone. Methods: After Institutional Ethics Committee approval, 102 ASA I-III patients scheduled for major orthopaedic surgery were recruited. All patients received 0.25 mg.kg-1 bupivacaine and 0.01 mg.kg-1 morphine intrathecally. Patients were randomised to one of three treatment groups and received: (Group A) dexamethasone 8mg, (Group B) ondansetron 8mg, and (Group C) dexamethasone 8mg and ondansetron 4mg. All treatments were administered intravenously. Patients were interviewed at 30 minutes, 2, 4, 8 and 24 hours following surgery. PONV and pruritus was evaluated using a visual analog scale by a blinded observer. Data was analysed using one way analysis of variance and Chi-square test as appropriate. Results: There were no adverse effects following drug administration. The three groups were similar in terms of age, weight, intrathecal opioid dose and duration of surgery. Combination therapy reduced the incidence of PONV compared to the use of dexamethasone alone (p=0.035). Combination therapy also demonstrated improved pruritus scores at four hours following surgery compared to ondansetron alone (1.98(2.2) vs 2.63(2.7), p=0.018). Conclusion: Combination of ondansetron plus dexamethasone significantly decreased the incidence of intrathecal opioid induced PONV and pruritis compared to monotherapy. The lower dose of ondansetron used in the combination group compared to ondansetron alone group has important cost implications.

(PDF emailed within 1 workday: $29.90)

Accession: 034622813

Download citation: RISBibTeXText

Related references

A comparison of dexamethasone, ondansetron, and dexamethasone plus ondansetron as prophylactic antiemetic and antipruritic therapy in patients receiving intrathecal morphine for major orthopedic surgery. Anesthesia and Analgesia 97(1): 259-63, Table of Contents, 2003

Dexamethasone versus a combination of dexamethasone and ondansetron as prophylactic antiemetic in patients receiving intrathecal morphine for caesarean section. African Health Sciences 14(2): 453-459, 2015

Comparison of Palonosetron, Dexamethasone, and Palonosetron Plus Dexamethasone as Prophylactic Antiemetic and Antipruritic Drug in Patients Receiving Intrathecal Morphine for Lower Segment Cesarean Section. Anesthesia, Essays and Researches 12(2): 322-327, 2018

Prospective randomized, double-blind comparative study of dexamethasone, ondansetron, and ondansetron plus dexamethasone as prophylactic antiemetic therapy in patients undergoing day-case gynaecological surgery. British Journal of Anaesthesia 87(4): 588-592, 2002

Prospective, Randomized, Double-Blind Comparative Study of Dexamethasone, Ondansetron, and Ondansetron Plus Dexamethasone As Prophylactic Antiemetic Therapy for Patients Undergoing Day-Case Gynaecological Surgery. Survey of Anesthesiology 46(3): 119-120, 2002

Prophylactic antiemetic effects in gynecologic patients receiving fentanyl IV-patient controlled analgesia: comparison of combined treatment with ondansetron and dexamethasone with metoclopramide and dexamethasone. Korean Journal of Anesthesiology 59(5): 335-339, 2010

Antiemetic prophylaxis against postoperative nausea and vomiting with ondansetron-dexamethasone combination compared to ondansetron or dexamethasone alone for patients undergoing laparoscopic cholecystectomy. Kathmandu University Medical Journal 6(23): 319-328, 2010

Comparison of antiemetic efficacy of ondansetron with dexamethasone plus domperidone in refractory nausea and vomiting in patients receiving non cisplatinum chemotherapy regimens. Journal of Cancer Research & Clinical Oncology 116(SUPPL PART 1): 640, 1990

Does ondansetron plus dexamethasone enhance the antiemetic efficacy of ondansetron?. Anesthesia & Analgesia 78(2 SUPPL ): ABSTRACT S280, 1994

Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy. Lancet 338(8765): 487-490, 1991

The antiemetic efficacy of oral ondansetron plus intravenous dexamethasone in patients with gynecologic malignancies receiving carboplatin-based chemotherapy. Gynecologic Oncology 78(1): 43-46, 2000

Comparison of ondansetron with ondansetron plus dexamethasone for antiemetic prophylaxis in children undergoing strabismus surgery. Journal of Pediatric Ophthalmology and Strabismus 41(2): 100-104, 2004

Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy. Journal of the Medical Association of Thailand 89 Suppl 4(): S29-S36, 2007

Comparison of ondansetron, dexamethasone, ondansetron plus dexamethasone and placebo in the prevention of nausea and vomiting after laparoscopic tubal ligation. Journal of the Indian Medical Association 101(11): 638, 640, 642-638, 640, 642, 2004

A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherapy. Pediatric Hematology and Oncology 17(6): 445-455, 2000